



Cell type specific delivery (CTSD™) enables efficient and selective transfection of specific immune cells both *ex vivo* and *in vivo*. **a**, Human PBMCs were treated with the SV-Delivery-2 and SV-Delivery-3 encapsulated mRNA encoding with eGFP to target human T cells and NK cells, respectively. Shown are the percentage of GFP positive cells in different cell types indicated in human PBMC at one day post treatment. **b**, Six- to eight-week-old Balb/c mice (n=5 per group) were intravenously injected with SV-Delivery-1 encapsulated mRNA encoding with eGFP to target mouse T cells. Shown are the percentage of GFP positive cells in splenic cells at day one post injection.